• Cyclin D inhibits the transcriptional activity of

  2020-06-10

  

  Cyclin D1 inhibits the transcriptional activity of the transcription factors myogenin and MEF2 [39,40]. In addition, myogenin activates MEF2 expression, which feeds back to amplify the myogenin promoter [38]. In this study, DGKδ suppression, in addition to the increase of cyclin D1, inhibited myoge

• br Methods br Results br Discussion MEN is a potent

  2020-06-10

  

  Methods Results Discussion MEN91507 is a potent and selective CysLT1 receptor antagonist. Guinea-pig lung membranes have been widely used for the detection and characterization of CysLT1 receptor antagonists: in this assay the high affinity (subnanomolar) binding of [3H[leukotriene D4 or [3

• CYP A is involved in the metabolism of approximately of

  2020-06-10

  

  CYP3A is involved in the metabolism of approximately 50% of all drugs that are currently prescribed to patients [1], [15], [16]. Marked interindividual variabilitity of the catalytic function for metabolizing CYP3A substrates has been demonstrated with variability exceeding 20-fold [1]. Levonorgestr

• Considering all these facts in the present

  2020-06-10

  

  Considering all these facts, in the present study, we investigated the effects of two highly selective CRF receptor 2 antagonists (antisavaugine-30, ASV-30; and astressin-2B, AST-2B) on anxiety behavior in rats. The rationale for such an experimental approach was based on the premise that fear and s

• Another well established visceral action

  2020-06-10

  

  Another well-established visceral action of CRF and urocortin administered peripherally is the long-lasting lowering of blood pressure observed in various species ranging from rodents to humans [22]. Existing evidence suggests that the hypotensive action of CRF and urocortin is mediated by the inter

• br Materials and methods br Results

  2020-06-10

  

  Materials and methods Results Discussion In the past decade, GWAS have attempted to identify genetic variants that confer risk for many human diseases, whose inherited components remain unexplained (Manolio et al., 2009). In a few cases risk variants identified by GWAS have paved the way fo

• MuRF and MuRF in http www

  2020-06-09

  

  MuRF1 and MuRF3 in cooperation with the E2 ubiquitin-conjugating enzymes UbcH5a, -b, and -c were found to mediate degradation of myosin heavy chain β/slow (MHC β/slow) and MHC IIa via UPS, both, in vitro and in vivo [60]. Mice lacking both MuRF1 and MuRF3 developed skeletal muscle myopathy and hyper

• br Introduction Diacylglycerol kinase DGK is a lipid metabol

  2020-06-09

  

  Introduction Diacylglycerol kinase (DGK) is a lipid-metabolizing enzyme that phosphorylates diacylglycerol (DG) to produce phosphatidic mitoxantrone synthesis (PA) [[1], [2], [3], [4]]. DG and PA act as lipid second messengers in a wide variety of biological processes. Ten DGK isozymes (α, β, γ,

• br Experimental Procedures br Acknowledgments The authors wi

  2020-06-09

  

  Experimental Procedures Acknowledgments The authors wish to thank P. Costet (University of Bordeaux) and Véronique Guyonnet-Duperat (FR TransBioMed, Plateforme de Vectorologie, University of Bordeaux) and Prof. Nils-Göran Larsson and Dr. Bettina Bertalan (Max Planck Institute for Biology of Ag

• Three kinase inhibitors dasatinib type I imatinib

  2020-06-09

  

  Three kinase inhibitors dasatinib (type I), imatinib (type II) and nilotinib (type II), identified initially as inhibitors of tyrosine kinase BCR-ABL, were found to target DDRs in a chemical proteomic profiling study (Bantscheff et al., 2007, Hantschel et al., 2008). These tyrosine kinase inhibitors

• br Methods br Results br Discussion

  2020-06-09

  

  Methods Results Discussion With this study, we provided evidence that acriflavine can interfere with EMT and UPR, two well-described pathways associated with cancer aggressiveness. And, because drug resistance is also clearly associated with the mesenchymal state [36], blocking of the epith

• br Introduction Epidermal growth factor receptor EGFR activa

  2020-06-09

  

  Introduction Epidermal growth factor receptor (EGFR)-activating-mutant non-small cell lung cancer (NSCLC) often initially responds well to EGFR tyrosine kinase inhibitors (TKIs) (Haber et al., 2011); however, the disease almost always recurs about 10–13 months of therapy. Analysis of clinical spe

• The repeat sequence TTAGGG of telomere

  2020-06-08

  

  The repeat sequence “TTAGGG” of telomere could be directly recognized by TERF1. TERF1 is indispensable for the maintenance of telomere meclozine structure and integrity (Tan et al., 2017). Trf1 genetic depletion in vivo induces a persistent DNA damage response and telomere uncapping, which effectiv

• In patients with CTEPH ET levels are raised and have

  2020-06-08

  

  In patients with CTEPH, ET-1 levels are raised and have been shown to fall after PEA surgery [24]. After an acute pulmonary embolism there is obstruction of the pulmonary CB-5083 receptor by acute thrombus and elevated levels of ET-1 [28], [30]. Elevated levels of ET-1 have also been observed in ai

• LVDP values of at the end

  2020-06-08

  

  LVDP values of ~80% at the end of reperfusion. L-NAME treatment did not modify the contractility detected in ischemic control hearts but annulled the actions of BZ acquiring LVDP values up to 40% (Fig. 4 A). A similar pattern was observed when +dP/dtmax was analysed (Fig. 4 B). LVEDP, as an index o

10916 records 514/728 page Previous Next First page 上5页 511512513514515 下5页 Last page